M/S Estonia 25 years ago

September 28, 2019

https://yle.fi/uutiset/3-10988379

M/S Estonia has been  built 1980, so it was not in bad condition. But , I think, The selected route was like  to chose   a “Bermuda “, the uncertainty, of Baltic Sea, in a big storm,  waves 4 – 10 meters from  some  unsuitable  directions. The ship  before ( Viking Sally)  had a route , mostly among the archipelago of Finland and  the  outer isles of  Stockholm, and the  stormy  channel from North to South was   quite a  short piece of the route (  normally only  4 hours high wave-  journey in  heavy crosswind at right angles).

The design of the ships to that kind of crosswind possibilities in  such a  lively traffic ( many cars , lorries, road trailer) should  be similar s  Stena Line has. They  go in  nearly everlasting crosswind and  stop going  if the cross wind  storm is  huge.

M/S Estonia  was not  suitable  to  a huge  cross  wind.  That my opinion.

About Denmark

September 25, 2019

https://danmarkshistorien.dk/leksikon-og-kilder/vis/materiale/joedeaktionen-og-evakueringen-af-danske-joeder-i-oktober-1943/

 

https://www.bbc.com/news/world-latin-america-49541485

 

Track hurricane Dorian

August 30, 2019

https://edition.cnn.com/interactive/storm-tracker/

This hurricane  can have a very serious  impact on Florida  on Monday 2th September  2019

https://www.ncbi.nlm.nih.gov/pubmed/?term=Gas6%2C+Axl+%2C+virus+%2C+dengue%2C+ebola

Thrombocyte

July 10, 2019

Recommendations and Guidelines Free Access
Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH
P. Gresele
for the Subcommittee on Platelet Physiology
First published: 18 November 2014
https://doi.org/10.1111/jth.12792
Cited by: 76
Manuscript handled by: S. Eichinger
Final decision: F. R. Rosendaal, 6 November 2014

 

Other articles  concerning rheology

from Milano University https://orcid.org/0000-0002-7343-4534

https://reliefweb.int/report/democratic-republic-congo/democratic-republic-congo-ebola-virus-disease-external-situation-56

As of 12 May 2019, a total of 1705 EVD cases, including 1617 confirmed and 88 probable cases, were reported. A total of 1124 deaths were reported (overall case fatality ratio 66%), including 1036 deaths among confirmed cases. Of the 1705 confirmed and probable cases with known age and sex, 56% (951) were female, and 29% (502) were children aged less than 18 years. The number of healthcare workers affected has risen to 101 (6% of total cases).

Ambassador of Brazil to Beirut dies

Search results
Items: 1 to 20 of 2136
<< FirstLast >>
Select item 31063571
1.

Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes.

[No authors listed]

JAMA. 2019 May 7;321(17):1720-1721. doi: 10.1001/jama.2019.2702. No abstract available.

PMID:
31063571

Similar articles
Select item 31060053
2.

Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases.

Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH.

Ann Intern Med. 2019 May 7. doi: 10.7326/M19-0085. [Epub ahead of print]

PMID:
31060053

Similar articles
Select item 31057401
3.

Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation.

Behnammanesh G, Durante ZE, Peyton KJ, Martinez-Lemus LA, Brown SM, Bender SB, Durante W.

Front Pharmacol. 2019 Apr 16;10:362. doi: 10.3389/fphar.2019.00362. eCollection 2019.

PMID:
31057401

Free Article

Similar articles
Select item 31050384
4.

Effects of sodium-glucose cotransporter 2 inhibitors on risk of venous thromboembolism in patients with type 2 diabetes: A systematic review and meta-analysis.

Wang A, Yang K, Wang T, Zhang N, Tang H, Feng X.

Diabetes Metab Res Rev. 2019 May 3:e3174. doi: 10.1002/dmrr.3174. [Epub ahead of print]

PMID:
31050384

Similar articles
Select item 31050116
5.

Acute Kidney Injury with sodium-glucose linked cotransporter-2 inhibitors: a meta-analysis of cardiovascular outcome trials.

Gilbert RE, Thorpe KE.

Diabetes Obes Metab. 2019 May 3. doi: 10.1111/dom.13754. [Epub ahead of print]

PMID:
31050116

Similar articles
Select item 31050099
6.

Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation between sglt2 inhibitors and dpp4 inhibitors using a supervised machine learning algorithm (profile study): A Retrospective analysis of a japanese commercial medical database.

Zhou FL, Watada H, Tajima Y, Berthelot M, Kang D, Esnault C, Shuto Y, Maegawa H, Koya D.

Diabetes Obes Metab. 2019 May 3. doi: 10.1111/dom.13753. [Epub ahead of print]

PMID:
31050099

Similar articles
Select item 31041781
7.

How Generalizable Are Cardiovascular Outcome Trials of Sodium-Glucose Co-Transporter-2 Inhibitors? A National Database Study: Study Protocol.

Hinton W, Feher MD, Munro N, de Lusignan S.

Diabetes Ther. 2019 Apr 30. doi: 10.1007/s13300-019-0620-8. [Epub ahead of print]

PMID:
31041781

Similar articles
Select item 31041606
8.

Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.

Chen Z, Li G.

Clin Drug Investig. 2019 Apr 30. doi: 10.1007/s40261-019-00781-w. [Epub ahead of print] Review.

PMID:
31041606

Similar articles
Select item 31033127
9.

Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.

Yurista SR, Silljé HHW, Oberdorf-Maass SU, Schouten EM, Pavez Giani MG, Hillebrands JL, van Goor H, van Veldhuisen DJ, de Boer RA, Westenbrink BD.

Eur J Heart Fail. 2019 Apr 29. doi: 10.1002/ejhf.1473. [Epub ahead of print]

PMID:
31033127

Similar articles
Select item 31032431
10.

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice.

Takahashi H, Nomiyama T, Terawaki Y, Horikawa T, Kawanami T, Hamaguchi Y, Tanaka T, Motonaga R, Fukuda T, Tanabe M, Yanase T.

Biochem Biophys Rep. 2019 Apr 19;18:100640. doi: 10.1016/j.bbrep.2019.100640. eCollection 2019 Jul.

PMID:
31032431

Free PMC Article

Similar articles
Select item 31030051
11.

Study on the interaction of ertugliflozin with human serum albumin in vitro by multispectroscopic methods, molecular docking, and molecular dynamics simulation.

Wang W, Gan N, Sun Q, Wu D, Gan R, Zhang M, Tang P, Li H.

Spectrochim Acta A Mol Biomol Spectrosc. 2019 Apr 18;219:83-90. doi: 10.1016/j.saa.2019.04.047. [Epub ahead of print]

PMID:
31030051

Similar articles
Select item 31027990
12.

Challenges in the Diagnosis of Euglycemic Diabetic Ketoacidosis in a Patient With Multiple Sclerosis Taking a Sodium-Glucose Cotransporter 2 Inhibitor.

Allison R, Goldstein D, Musso MW.

J Emerg Med. 2019 Apr 23. pii: S0736-4679(19)30137-4. doi: 10.1016/j.jemermed.2019.03.011. [Epub ahead of print]

PMID:
31027990

Similar articles
Select item 31026402
13.

SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018).

Pandey J, Tamrakar AK.

Expert Opin Ther Pat. 2019 Apr 26:1-16. doi: 10.1080/13543776.2019.1612879. [Epub ahead of print]

PMID:
31026402

Similar articles
Select item 31026373
14.

The protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease, and type 2 diabetes.

Miyoshi H, Kameda H, Yamashita K, Nakamura A, Kurihara Y.

J Diabetes Investig. 2019 Apr 26. doi: 10.1111/jdi.13064. [Epub ahead of print]

PMID:
31026373

Free Article

Similar articles
Select item 31026084
15.

Pharmacokinetic and Pharmacodynamic Modeling for Renal Function Dependent Urinary Glucose Excretion Effect of Ipragliflozin, a Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, Both in Healthy Subjects and Patients with Type 2 Diabetes Mellitus.

Saito M, Kaibara A, Kadokura T, Toyoshima J, Yoshida S, Kazuta K, Ueyama E.

Br J Clin Pharmacol. 2019 Apr 26. doi: 10.1111/bcp.13972. [Epub ahead of print]

PMID:
31026084

Similar articles
Select item 31016172
16.

Fournier’s Gangrene and Sodium-glucose Co-transporter 2(SGLT2) Inhibitors: Our Experience.

Dass AS, Immaculate G, Bhattacharyya A.

Indian J Endocrinol Metab. 2019 Jan-Feb;23(1):165-166. doi: 10.4103/ijem.IJEM_614_18. No abstract available.

PMID:
31016172

Free PMC Article

Similar articles
Select item 31016169
17.

Sodium Glucose Co-transporter-2 Inhibitor: Benefits beyond Glycemic Control.

Baruah MP, Makkar BM, Ghatnatti VB, Mandal K.

Indian J Endocrinol Metab. 2019 Jan-Feb;23(1):140-149. doi: 10.4103/ijem.IJEM_160_17. Review.

PMID:
31016169

Free PMC Article

Similar articles
Select item 31016146
18.

High Prevalence of Genital Mycotic Infections with Sodium-glucose Co-transporter 2 Inhibitors among Indian Patients with Type 2 Diabetes.

Aggarwal A, Wadhwa R, Kapoor D, Khanna R.

Indian J Endocrinol Metab. 2019 Jan-Feb;23(1):9-13. doi: 10.4103/ijem.IJEM_244_18.

PMID:
31016146

Free PMC Article

Similar articles
Select item 31005757
19.

Assessment of the benefit-risk balance of SGLT2 inhibitors: Commentary on a new ‘French paradox’.

Scheen AJ, Darmon P, Hanaire H; writing committee of the position statement by the French-Speaking Society of Diabetes (SFD).

Diabetes Metab. 2019 Apr 18. pii: S1262-3636(19)30061-8. doi: 10.1016/j.diabet.2019.04.001. [Epub ahead of print] No abstract available.

PMID:
31005757

Similar articles
Select item 31004234
20.

Inhibition of sodium-glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization.

Baker HE, Kiel AM, Luebbe ST, Simon BR, Earl CC, Regmi A, Roell WC, Mather KJ, Tune JD, Goodwill AG.

Basic Res Cardiol. 2019 Apr 19;114(3):25. doi: 10.1007/s00395-019-0733-2.

PMID:
31004234

Similar articles

https://www.bbc.com/news/world-latin-america-48030691

Venezuela , a rich oil producer coutnry-  do not manage to  give  drinking water to its   over 30  million people.

Leaders  seem  have much  personal  quarrels, antipaties , iontolerances   and  fights,  and own intresses ,lacking   ability to diplomacy and responsible  ruling over nations´s    multimillion multitudes which  still are   waiting  a Good  Shephard  in this  world time, but they are  only   suffering still  every day more. Even death toll  because of miseries  is going upwards.  The worsest thing is  man made deaths:  violent cruel killings of   civilians.

It is a civil wsar:  most cruel of all wars:   A neighbour killing  neighbours.

 

MOST IMPORTANT LIVELIHOOD  is  SAFE WATER:

 

Leabright's Blog

Just another WordPress.com weblog

WordPress.com

WordPress.com is the best place for your personal blog or business site.